Benign Genitourinary Tumors — VA Rating (DC 7529)

Diagnostic Code 7529 · 38 CFR §4.115b

What Is It?

DC 7529 covers benign, meaning non-cancerous, tumors anywhere in the genitourinary system: renal angiomyolipomas and oncocytomas, bladder papillomas, ureteral polyps, and similar growths. Benign does not mean harmless. A tumor in this system can bleed, obstruct the flow of urine, force removal of part or all of a kidney, and require surveillance imaging for the rest of your life. Some are found by accident on a scan ordered for something else, and some announce themselves with blood in the urine or with flank pain. Under 38 CFR §4.115b the entry carries no percentages. It instructs: rate as voiding dysfunction or renal dysfunction, whichever is predominant. So the evaluation is entirely about what the tumor and its treatment did to function. If the growth obstructs or irritates the bladder and outlet, the voiding dysfunction formulas apply and reach 60 percent. If it cost you kidney tissue — through partial nephrectomy, embolization, or pressure damage — the renal dysfunction criteria apply, which are graded on glomerular filtration rate and reach 100 percent. A veteran who has lost part of a kidney should be evaluated on the renal side, and that requires a current GFR in the file.

Rating Criteria

Evidence Needed

Establish first that the tumor is benign, because that is what places the claim under this code rather than DC 7528: the pathology report from a biopsy or resection, or imaging characteristic enough that the radiologist names it. Then document function on both possible paths. For the renal path, a creatinine series with calculated GFR over at least a year, a urine albumin/creatinine ratio, and the operative report if part of a kidney was removed, plus any split-function renal scan showing how much the remaining tissue contributes. For the voiding path, a post-void residual, uroflowmetry, a voiding diary, and a pad count if you leak. Surveillance imaging showing size, growth, or stability supports both the ongoing nature of the condition and the need for continued monitoring.

C&P Exam Tips

State early that the tumor was benign and hand over the pathology, then move the conversation to function, because function is the entire evaluation. If part of a kidney was removed or embolized, say so and ask that a current creatinine with GFR be obtained, since the renal path reaches 80 and 100 percent while the voiding path stops at 60. If the tumor obstructs or irritates the bladder, bring the voiding diary and give intervals and night-time counts rather than adjectives. Mention bleeding episodes with dates, any procedure to control them, and whether you have needed catheterization. Ask which formula is being applied and request that both be considered so the predominant one governs.

How to File

File on VA Form 21-526EZ naming the specific benign tumor under DC 7529, and request evaluation under both the voiding dysfunction and renal dysfunction criteria of 38 CFR §4.115a so the predominant one applies. Attach the pathology or characteristic imaging, the operative report, the GFR series, a urine albumin/creatinine ratio, and the voiding evidence. If the tumor is attributable to a service-connected condition or to a documented exposure, say so and cite it. Claim resulting chronic kidney disease, hypertension, and anemia as separate issues under 38 CFR §3.310. If a tumor previously called benign is later found malignant, file a supplemental claim promptly with the new pathology, because the evaluation moves to DC 7528 and its 100 percent provisions.

Common Mistakes

The first mistake is not filing at all because the tumor is benign. The code exists precisely for benign growths, and the evaluation follows the functional loss, not the pathology. The second is letting the claim be decided on voiding symptoms when kidney tissue was lost, which caps the evaluation at 60 percent when the renal path reaches 100. The third is submitting no current GFR, which makes the renal path unevaluable no matter how much kidney was removed. The fourth is treating a resected tumor as a closed file when surveillance imaging, reduced function, hypertension, and recurrence risk all continue. The fifth is missing the anemia that follows repeated bleeding, which is separately evaluated under the hemic codes.

Frequently Asked Questions

Why does a benign tumor get rated at all?

Because the schedule compensates functional loss, not malignancy. A benign growth can obstruct urine flow, bleed enough to cause anemia, and require removal of kidney tissue that never comes back. DC 7529 directs that the condition be rated as voiding dysfunction or renal dysfunction, whichever is predominant, which means the evaluation is built from what the tumor and its treatment cost you in function. A veteran with a benign renal tumor and a partial nephrectomy can be rated substantially.

Can benign kidney cysts be service connected?

Simple cysts are common and usually age-related, which makes service connection difficult without something more. Complex cysts, multiple cysts, cysts tied to a documented exposure, or cysts appearing in service records are a different matter. Note also that inherited cystic kidney diseases such as polycystic kidney disease are covered by DC 7533 rather than this code. If your cysts are numerous or complex, ask the urologist to address the etiology directly rather than defaulting to age.

I had part of my kidney removed. How should that be rated?

On the renal dysfunction criteria, which are graded on glomerular filtration rate and reach 80 and 100 percent, rather than on voiding symptoms which stop at 60. The evidence that makes this possible is a creatinine series with calculated GFR held at a level for at least 3 consecutive months during the past 12, plus the operative report. Ask specifically for renal dysfunction consideration, because a claim that only describes urinary symptoms will be evaluated where those symptoms live.

What if the tumor turns out to be malignant later?

File a supplemental claim immediately with the new pathology. Malignant genitourinary neoplasms are evaluated under DC 7528 at 100 percent, continuing beyond the cessation of surgical, X-ray, antineoplastic chemotherapy, or other therapeutic procedure, with a mandatory VA examination at six months. Having the benign condition already service connected simplifies the transition considerably, because service connection is established and only the evaluation and code change.

Does the monitoring itself count for anything?

Indefinite surveillance is not a rating criterion on its own, and no percentage attaches to having scans. What can be claimed is a psychiatric condition that developed from living with an unresolved growth, filed as secondary under 38 CFR §3.310 and supported by a mental health evaluation. Keep the surveillance imaging regardless, because it documents the condition's persistence and gives you a size history if it grows.